Aurobindo Pharma has announced that it has received approval from the US Food and Drug Administration (USFDA) for its Glycerol Phenylbutyrate Oral Liquid, marking a significant addition to its portfolio of specialty and complex formulations. The approved product is a generic equivalent of Ravicti Oral Liquid and is indicated for the chronic management of patients with Urea Cycle Disorders (UCDs).
These rare genetic conditions impair the body’s ability to remove ammonia from the bloodstream, potentially leading to serious health complications if left untreated. The medication plays a critical role in helping patients manage ammonia levels and improve long-term health outcomes.
This approval underscores Aurobindo Pharma’s continued focus on expanding its presence in the specialty and rare disease segments, particularly in the United States, one of its key markets. The addition of Glycerol Phenylbutyrate Oral Liquid further strengthens the company’s differentiated product pipeline and enhances its ability to address unmet medical needs.
According to the company, the product will be manufactured at its USFDA-approved facilities, ensuring adherence to stringent global quality and compliance standards. The launch is expected to improve patient access to an affordable treatment alternative, especially in a therapeutic area where options are limited and often costly.
Aurobindo Pharma has steadily built a strong presence in the global generics market, with a diversified portfolio spanning antibiotics, antiretrovirals, cardiovascular, central nervous system, and gastroenterology products. The company has also been increasing its investments in complex generics, injectables, and specialty formulations to drive long-term growth.
The USFDA approval is expected to contribute to Aurobindo Pharma’s revenue growth in the coming years, while reinforcing its reputation as a reliable supplier of complex generic medicines. It also aligns with the company’s broader objective of enhancing healthcare accessibility and supporting patients with critical medical needs.
Founded in 1986, Aurobindo Pharma is a leading global pharmaceutical company headquartered in India. It develops, manufactures, and markets a wide range of generic and branded pharmaceutical products across more than 150 countries. The company operates a robust manufacturing and R&D infrastructure, supported by regulatory approvals from major global agencies, including the USFDA.
